Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma

NCT00095693 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00095693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00095693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2004
Completion date
December 31, 2011
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic thyroid cancer, insular thyroid cancer, recurrent thyroid cancer, stage iii follicular thyroid cancer, stage iii papillary thyroid cancer, stage iv follicular thyroid cancer, stage iv papillary thyroid cancer